AIRNA develops RNA‑editing therapeutics using its RESTORE+ platform that programs oligonucleotides to recruit endogenous ADAR, advancing a lead AIR‑001 candidate for alpha‑1 antitrypsin deficiency and a multi‑program pipeline.
airna.comPart of: Boston tech scene from Fundable